Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hodgkin's lymphoma in first relapse following chemotherapy or combined modality therapy: analysis of outcome and prognostic factors after conventional salvage therapy.
Vassilakopoulos TP, Angelopoulou MK, Siakantaris MP, Kontopidou FN, Dimopoulou MN, Boutsis DE, Anargyrou K, Kokoris SI, Giannakakis A, Karkantaris C, Kyrtsonis MC, Tsaftaridis P, Rombos J, Variamis E, Korkolopoulou P, Kittas C, Pangalis GA. Vassilakopoulos TP, et al. Among authors: karkantaris c. Eur J Haematol. 2002 May;68(5):289-98. doi: 10.1034/j.1600-0609.2002.01721.x. Eur J Haematol. 2002. PMID: 12144535
Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma.
Vassilakopoulos TP, Angelopoulou MK, Siakantaris MP, Kontopidou FN, Dimopoulou MN, Kokoris SI, Kyrtsonis MC, Tsaftaridis P, Karkantaris C, Anargyrou K, Boutsis DE, Variamis E, Michalopoulos T, Boussiotis VA, Panayiotidis P, Papavassiliou C, Pangalis GA. Vassilakopoulos TP, et al. Among authors: karkantaris c. Int J Radiat Oncol Biol Phys. 2004 Jul 1;59(3):765-81. doi: 10.1016/j.ijrobp.2003.11.029. Int J Radiat Oncol Biol Phys. 2004. PMID: 15183480
Prognostic factors in advanced stage Hodgkin's lymphoma: the significance of the number of involved anatomic sites.
Vassilakopoulos TP, Angelopoulou MK, Siakantaris MP, Kontopidou FN, Dimopoulou MN, Barbounis A, Grigorakis V, Karkantaris C, Anargyrou K, Chatziioannou M, Rombos J, Boussiotis VA, Vaiopoulos G, Kittas C, Pangalis GA. Vassilakopoulos TP, et al. Among authors: karkantaris c. Eur J Haematol. 2001 Nov-Dec;67(5-6):279-88. doi: 10.1034/j.1600-0609.2001.00561.x. Eur J Haematol. 2001. PMID: 11872075
beta(2)-microglobulin in Hodgkin's lymphoma: prognostic significance in patients treated with ABVD or equivalent regimens.
Vassilakopoulos TP, Nadali G, Angelopoulou MK, Dimopoulou MN, Siakantaris MP, Kontopidou FN, Karkantaris C, Kokoris SI, Dimitriadou EM, Calpadaki C, Sarantopoulos A, Galani Z, Sachanas S, Kyrtsonis MC, Tsaftaridis P, Variamis E, Panayotidis P, Pizzolo G, Sarris AH, Pangalis GA. Vassilakopoulos TP, et al. Among authors: karkantaris c. J BUON. 2005 Jan-Mar;10(1):59-69. J BUON. 2005. PMID: 17335133
The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio.
Terpos E, Mihou D, Szydlo R, Tsimirika K, Karkantaris C, Politou M, Voskaridou E, Rahemtulla A, Dimopoulos MA, Zervas K. Terpos E, et al. Among authors: karkantaris c. Leukemia. 2005 Nov;19(11):1969-76. doi: 10.1038/sj.leu.2403890. Leukemia. 2005. PMID: 16079895 Clinical Trial.
Treatment of Waldenström's macroglobulinemia with rituximab.
Dimopoulos MA, Zervas C, Zomas A, Kiamouris C, Viniou NA, Grigoraki V, Karkantaris C, Mitsouli C, Gika D, Christakis J, Anagnostopoulos N. Dimopoulos MA, et al. Among authors: karkantaris c. J Clin Oncol. 2002 May 1;20(9):2327-33. doi: 10.1200/JCO.2002.09.039. J Clin Oncol. 2002. PMID: 11981004 Clinical Trial.
12 results